Form 8-K - Current report:
SEC Accession No. 0001193125-20-304907
Filing Date
2020-11-30
Accepted
2020-11-30 07:04:31
Documents
13
Period of Report
2020-11-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d76031d8k.htm   iXBRL 8-K 25719
2 EX-99.1 d76031dex991.htm EX-99.1 22382
  Complete submission text file 0001193125-20-304907.txt   176098

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrna-20201130.xsd EX-101.SCH 3095
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrna-20201130_lab.xml EX-101.LAB 17375
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrna-20201130_pre.xml EX-101.PRE 10970
6 EXTRACTED XBRL INSTANCE DOCUMENT d76031d8k_htm.xml XML 3228
Mailing Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 201356261
SIC: 2836 Biological Products, (No Diagnostic Substances)